China Hospital Drug Buying Slows, Biologics Outpace Market In 2013: McKinsey And CPA
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug sales monitored at select hospitals in China rose at a double digit rate in 2013, but that is still a slower pace than in recent years as the impact of a compliance storm hit. Biologics however gained faster than small molecules and show potential for even greater growth, according to a recent report from global consulting firm McKinsey & Co and the Chinese Pharmaceutical Association.